Pharmacoeconomic Evaluation Of Trastuzumab Emtansine And Pertuzumab Treatments In Metastatic Breast Cancer Patients

Abstract

Purpose: We aimed to perform a cost-effectiveness analysis for trastuzumab emtansine (TDM-1) and pertuzumab treatments in patients with HER-2 positive metastatic breast cancer. Method: Patients were detected retrospectively who diagnosed with HER-2 positive metastatic breast cancer and treated with pertuzumab or TDM-1 between 11.2016 - 11.2019 in our hospital. Demographic data, drug doses and periods obtained from the patients' medical records. The evaluated pharmacoeconomic outcomes were quality adjusted life years (QALYs), progression-free survival durations and treatment costs. Results: Treatment with TDM-1 resulted in a mean progression-free survival of 10.5 months. Mean progression-free survival in pertuzumab administered patients was 19 months. In our cost-effectiveness analysis in HER-2 positive metastatic breast cancer resulted in an additional 1.91 life-years gained, at a cost of 69.334 United States Dollars ($) per QALYs in pertuzumab. Also, it was determined an additional 1.75 life-years gained and a cost of 19.255 $ per QALYs in TDM-1. In pertuzumab treatment, progression-free survival was found to be significantly higher compared to TDM-1 (p < 0.001). On the other hand, the cost of this treatment was determined to be approximately 3.5 fold higher than TDM-1. Conclusion: In the study, both treatments were found to be statistically cost-effective. Larger study populations and multi-center studies are needed to more precisely demonstrate the pharmacoeconomic data in this subject.